HALO
NASDAQHalozyme Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$109.35+0.32 (+0.29%)
01:30 PM07:45 PM
News · 26 weeks55+200%
2026-03-012026-08-23
Mix2390d
- Insider12(52%)
- SEC Filings4(17%)
- Other2(9%)
- Leadership2(9%)
- Earnings2(9%)
- Analyst1(4%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Appelhans Dannielle3 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERPRESIDENT AND CEO Torley Helen exercised 60,000 shares at a strike of $18.41 and sold $6,275,592 worth of shares (60,000 units at $104.59) as part of a pre-agreed trading plan (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHalozyme Appoints Dannielle Appelhans to its Board of DirectorsSAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management."Dannielle brings a rare combination of operational excellence and manufacturing depth that aligns directly with our growth strategy, and we are delighted to welcome her to the Halozyme board," said Dr. Helen Torley, President and Chief Executive Officer. "As we continue to scale ENHANZE as a compounding platform engine and a
- INSIDERDirector Connaughton Bernadette sold $167,153 worth of shares (1,626 units at $102.80) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,418 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- ANALYSTHalozyme Therapeutics upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Halozyme Therapeutics from Market Perform to Outperform and set a new price target of $110.00
- SECSEC Form 10-Q filed by Halozyme Therapeutics Inc.10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCETotal Revenue Increased 48% YOY to $481 millionRoyalty Revenue Increased 50% YOY to $308 millionRaises 2026 Financial Guidance Ranges:Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37%Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43%Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95%1Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108% - 117%1Signed Five New ENHANZE® and Hypercon™ Collaboration Agreements YTD 2026, Exceeding Goal of Three for Full Year 2026SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter
- PRHalozyme to Report Second Quarter 2026 Financial and Operating ResultsSAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading.Halozyme will host a conference call on Thursday, August 6, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/838122249?pwd=X5tkHKiyA live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.About HalozymeHalozyme is a biopharmaceutical company a
- PRHalozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® TechnologyAgreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targetsSAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focu
- INSIDERPRESIDENT AND CEO Torley Helen exercised 1,923 shares at a strike of $12.07 and sold $153,391 worth of shares (1,923 units at $79.77) as part of a pre-agreed trading plan (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDEREVP, PRESIDENT, DRUG DELIVERY Ramsay David A converted options into 10,000 shares and covered exercise/tax liability with 5,408 shares (SEC Form 4) (withholding tax)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERSEC Form 4 filed by SVP, Chief Financial Officer Snellgrove Darren4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Connaughton Bernadette sold $124,651 worth of shares (1,625 units at $76.71) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 42,044 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- INSIDERDirector Krishnan Mahesh exercised 7,304 shares at a strike of $38.46 and sold $547,800 worth of shares (7,304 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRHalozyme Appoints David Ramsay as President Drug DeliverySAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026.In this newly created role, Mr. Ramsay will have an enterprise-wide, cross-technology mandate, and will be responsible for driving the growth of Halozyme's drug delivery technologies by establishing clear strategic priorities and assuring best in class business development and alliance management. David will report to Helen Torley, President and Chief Executive Officer."I am delighted to have a business leader of David's experience assume this new position at a time of unprecedented
- INSIDERSVP, CHIEF LEGAL OFFICER Snyder Mark Howard converted options into 5,034 shares and covered exercise/tax liability with 2,715 shares, increasing direct ownership by 5% to 49,929 units (SEC Form 4) to satisfy withholding obligation4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRHalozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on June 12, 2026."Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035. Importantly, there is also no projected impact on the Company's ability to execute new ENHANZE® p
- INSIDERSEC Form 3 filed by new insider Snellgrove Darren3 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERPRESIDENT AND CEO Torley Helen sold $3,370,008 worth of shares (50,000 units at $67.40) as part of a pre-agreed trading plan and exercised 50,000 shares at a strike of $12.07 (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Connaughton Bernadette sold $107,591 worth of shares (1,625 units at $66.21) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 43,669 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERPRESIDENT AND CEO Torley Helen exercised 50,000 shares at a strike of $12.07 and sold $3,433,875 worth of shares (50,000 units at $68.68) as part of a pre-agreed trading plan (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECSEC Form 10-Q filed by Halozyme Therapeutics Inc.10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
HALO FAQ
6 questionsWhat does Halozyme Therapeutics Inc. do?
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for...Where does HALO stock trade?
Halozyme Therapeutics Inc. (HALO) is listed on NASDAQ.What sector and industry is HALO in?
Halozyme Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about HALO?
Halozyme Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform on 2026-08-07. Recent price targets cluster around $4700.00.What companies are similar to HALO?
Notable peers in the same industry include TPTX (Turning Point Therapeutics Inc.), CBAY (CymaBay Therapeutics Inc.), CDTX (Cidara Therapeutics Inc.). Compare HALO side-by-side with any of them on Quantisnow.How can I track HALO on Quantisnow?
Quantisnow aggregates Halozyme Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HALO to receive live email and push alerts on every new disclosure.